DelveInsight’s, “Treatment Resistant Depression Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Treatment Resistant Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Treatment-Resistant Depression Pipeline Report

 

• DelveInsight’s Treatment-Resistant Depression Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Me Treatment-Resistant Depression treatment.

 

• The leading Treatment-Resistant Depression Companies includes Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.

 

• Promising Treatment-Resistant Depression Pipeline Therapies includes PCN-101, Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Psilocybin, NV-5138, CX157 (TriRima), Fluoxetine, and others.

 

• The Treatment-Resistant Depression companies and academics are working to assess challenges and seek opportunities that could influence Treatment Resistant Depression R&D. The Treatment-Resistant Depression pipeline therapies under development are focused on novel approaches to treat/improve Treatment Resistant Depression.

 

To explore more information on the latest breakthroughs in the Treatment-Resistant Depression Pipeline treatment landscape of the report, click here @ Treatment-Resistant Depression Pipeline Outlook

 

Treatment-Resistant Depression Overview

 

The term “treatment-resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment. Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.

 

Treatment-Resistant Depression Emerging Drugs Profile

 

Psilocybin: COMPASS Pathways

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.

 

AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor.

For further information, refer to the detailed Treatment-Resistant Depression Unmet Needs, Treatment-Resistant Depression Market Drivers, and Treatment-Resistant Depression Market Barriers, click here for Treatment-Resistant Depression Ongoing Clinical Trial Analysis

 

Treatment-Resistant Depression Pipeline Therapeutics Assessment

 

There are approx. 25+ key companies which are developing the therapies for Treatment Resistant Depression. The companies which have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. preregistration include, Axsome Therapeutics.

 

Treatment-Resistant Depression Pipeline: Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Request a sample and discover the recent advances in Treatment-Resistant Depression Ongoing Clinical Trial Analysis and Medications, click here @ Treatment-Resistant Depression Treatment Landscape

 

Scope of the Treatment-Resistant Depression Pipeline Report

 

• Coverage- Global

 

• Treatment-Resistant Depression Companies- Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.

 

• Treatment-Resistant Depression Pipeline Therapies- PCN-101, Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Psilocybin, NV-5138, CX157 (TriRima), Fluoxetine, and others.
• Treatment-Resistant Depression Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Treatment-Resistant Depression Market Drivers and Treatment-Resistant Depression Market Barriers, click here @ Treatment-Resistant Depression Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Treatment Resistant Depression: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Preregistration)
7. AXS-05: Axsome Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Psilocybin: COMPASS Pathways
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. SEP-378614: Sumitomo Dainippon Pharma
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Treatment Resistant Depression Key Companies
20. Treatment Resistant Depression Key Products
21. Treatment Resistant Depression- Unmet Needs
22. Treatment Resistant Depression- Market Drivers and Barriers
23. Treatment Resistant Depression- Future Perspectives and Conclusion
24. Treatment Resistant Depression Analyst Views
25. Treatment Resistant Depression Key Companies
26. Appendix

 

Got Queries? Find out the related information on Treatment-Resistant Depression Mergers and acquisitions, Treatment-Resistant Depression Licensing Activities @ Treatment-Resistant Depression Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/